Luis D Godoy1, Julianna E Lucas2, Abigail J Bender2, Samantha S Romanick3, Bradley S Ferguson1. 1. Department Agriculture, Nutrition, & Veterinary Sciences, University of Nevada, Reno, NV, USA. 2. Department of Biochemistry and Molecular Biology, University of Nevada, Reno, NV, USA. 3. Department of Pharmacology, University of Nevada, Reno, NV, USA.
Abstract
SCOPE: Nutrigenomics is a rapidly expanding field that elucidates the link between diet-genome interactions. Recent evidence demonstrates that regulation of the epigenome, and in particular inhibition of histone deacetylases (HDACs), impact pathogenetic mechanisms involved in chronic disease. Few studies, to date, have screened libraries of bioactive compounds that act as epigenetic modifiers. This study screened a library of 131 natural compounds to determine bioactive compounds that inhibit Zn-dependent HDAC activity. METHODS AND RESULTS: Using class-specific HDAC substrates, we screened 131 natural compounds for HDAC activity in bovine cardiac tissue. From this screen, we identified 18 bioactive compound HDAC inhibitors. Using our class-specific HDAC substrates, we next screened these 18 bioactive compounds against recombinant HDAC proteins. Consistent with inhibition of HDAC activity, these compounds were capable of inhibiting activity of individual HDAC isoforms. Lastly, we report that treatment of H9c2 cardiac myoblasts with bioactive HDAC inhibitors was sufficient to increase lysine acetylation as assessed via immunoblot. CONCLUSION: This study provided the first step in identifying multiple bioactive compound HDAC inhibitors. Taken together, this report sets the stage for future exploration of these bioactive compounds as epigenetic regulators to potentially ameliorate chronic disease.
SCOPE: Nutrigenomics is a rapidly expanding field that elucidates the link between diet-genome interactions. Recent evidence demonstrates that regulation of the epigenome, and in particular inhibition of histone deacetylases (HDACs), impact pathogenetic mechanisms involved in chronic disease. Few studies, to date, have screened libraries of bioactive compounds that act as epigenetic modifiers. This study screened a library of 131 natural compounds to determine bioactive compounds that inhibit Zn-dependent HDAC activity. METHODS AND RESULTS: Using class-specific HDAC substrates, we screened 131 natural compounds for HDAC activity in bovine cardiac tissue. From this screen, we identified 18 bioactive compound HDAC inhibitors. Using our class-specific HDAC substrates, we next screened these 18 bioactive compounds against recombinant HDAC proteins. Consistent with inhibition of HDAC activity, these compounds were capable of inhibiting activity of individual HDAC isoforms. Lastly, we report that treatment of H9c2 cardiac myoblasts with bioactive HDAC inhibitors was sufficient to increase lysine acetylation as assessed via immunoblot. CONCLUSION: This study provided the first step in identifying multiple bioactive compound HDAC inhibitors. Taken together, this report sets the stage for future exploration of these bioactive compounds as epigenetic regulators to potentially ameliorate chronic disease.
Authors: Douglas D Lemon; Todd R Horn; Maria A Cavasin; Mark Y Jeong; Kurt W Haubold; Carlin S Long; David C Irwin; Sylvia A McCune; Eunhee Chung; Leslie A Leinwand; Timothy A McKinsey Journal: J Mol Cell Cardiol Date: 2011-04-23 Impact factor: 5.000
Authors: Pierre Tessier; David V Smil; Amal Wahhab; Silvana Leit; Jubrail Rahil; Zuomei Li; Robert Déziel; Jeffrey M Besterman Journal: Bioorg Med Chem Lett Date: 2009-08-07 Impact factor: 2.823
Authors: Marielle Fournel; Claire Bonfils; Yu Hou; Pu Theresa Yan; Marie-Claude Trachy-Bourget; Ann Kalita; Jianhong Liu; Ai-Hua Lu; Nancy Z Zhou; Marie-France Robert; Jeffrey Gillespie; James J Wang; Hélène Ste-Croix; Jubrail Rahil; Sylvain Lefebvre; Oscar Moradei; Daniel Delorme; A Robert Macleod; Jeffrey M Besterman; Zuomei Li Journal: Mol Cancer Ther Date: 2008-04 Impact factor: 6.261
Authors: Eunah Kim; William H Bisson; Christiane V Löhr; David E Williams; Emily Ho; Roderick H Dashwood; Praveen Rajendran Journal: Curr Top Med Chem Date: 2016 Impact factor: 3.295
Authors: Cole Schonhofer; Jennifer Yi; Amanda Sciorillo; Kerstin Andrae-Marobela; Alan Cochrane; Marianne Harris; Zabrina L Brumme; Mark A Brockman; Karam Mounzer; Colin Hart; Kwasi Gyampoh; Zhe Yuan; Luis J Montaner; Ian Tietjen Journal: Biochem Pharmacol Date: 2021-02-10 Impact factor: 5.858
Authors: Fabian Stahl; Philip Denner; Dominik Piston; Bernd O Evert; Laura de Boni; Ina Schmitt; Peter Breuer; Ullrich Wüllner Journal: Sci Rep Date: 2021-10-06 Impact factor: 4.379